Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Philip Morris International Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $284.5B | |
|---|---|---|
| Revenue (ttm) | 43.1B | |
| Net income (ttm) | 10.7B | |
| EPS (ttm) | $6.85 | |
| Shares out | 1.6B | |
| P/E (trailing) | 29.6x | |
| P/E (forward) | 20.4x | |
| Dividend | $6.40 (3.16%) | |
| Volume | 2,235,197 | |
| Beta | 0.36 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $31.41B | $31.76B | $35.17B | $37.88B | $40.65B | +6.7% |
| Gross profit | $21.38B | $20.36B | $22.28B | $24.55B | $27.28B | +6.3% |
| Operating income | $12.98B | $12.25B | $11.56B | $13.40B | $14.89B | +3.5% |
| Net income | $9.11B | $9.05B | $7.81B | $7.06B | $11.35B | +5.6% |
| EPS (diluted) | $5.83 | $5.81 | $5.02 | $4.52 | $7.26 | +5.6% |
| EBITDA | $2.93B | $13.48B | $13.37B | $15.75B | $17.46B | +56.3% |
| R&D | $617.0M | $642.0M | $709.0M | $759.0M | $756.0M | +5.2% |
| SG&A | $8.42B | $8.11B | $10.06B | $11.15B | $11.75B | +8.7% |
Recent company headlines from major financial publishers.
The base path requires FY2027 revenue and adjusted EPS near analyst forecasts as of 2026-09-09. Each annual update should test whether Europe revenue growth remains positive and reported profit keeps turning into operating cash. Europe stagnation or weaker cash generation would disconfirm the path.
The path gains support if FY2027 revenue and adjusted EPS exceed dated expectations while free cash flow remains strong. Positive Europe growth must also continue; Europe stagnation would disconfirm the path.
| Ke ↓ / g → | 2.6% | 3.1% | 3.6% | 4.1% | 4.6% |
|---|---|---|---|---|---|
| 5.6% | $285 | $324 | $392 | $559 | $587 |
| 6.4% | $244 | $265 | $296 | $346 | $447 |
| 7.1% | $217 | $230 | $249 | $273 | $311 |
| 7.8% | $199 | $207 | $219 | $233 | $254 |
| 8.5% | $185 | $191 | $199 | $208 | $221 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
